Could the active ingredient in
marijuana, responsible for its characteristic “high,” help turn the tide
against the accelerating Alzheimer’s epidemic?
A remarkable study published in the journal Molecular Pharmacology in 2006, found that this long vilified plant contains a compound with not one, but two therapeutic
properties ideal for addressing both the surface symptom (memory
problems) and root cause (brain plaque) of Alzheimer’s disease. This is
an ironic finding, considering that the prevailing stereotype is that
using marijuana “fries” the brain, leading to debilitating memory
issues.
On the first account, THC’s ability to inhibit the AChE enzyme, is not unlike the mechanism of action behind most Alzheimer’s drugs on the market today.
Drugs like donepezil (trade name Aricept), for instance, by targeting and inhibiting the brain enzyme acetylcholinesterase (AChE), result in an increase in brain levels of this neurotransmitter, which in turn, results in symptom reduction, i.e. improved memory. Donepezil, however, is riddled with controversy due its well-known association with seizures, which likely reflects its intrinsic neurotoxicity.
It is, in fact, a chemical in the same general chemical class as venom, insecticides and chemical war agents, such as nerve gas.
On the second account, THC’s ability to prevent the acetylcholinesterase-associated amyloid β-peptide (Aβ) aggregation, i.e. brain plaque, indicates that it may, as the researchers noted, “directly impact Alzheimer’s disease pathology.”
In fact, they found “Compared to currently approved drugs prescribed for the treatment of Alzheimer’s disease, THC is a considerably superior inhibitor of Aβ aggregation, and this study provides a previously unrecognized molecular mechanism through which cannabinoid molecules may directly impact the progression of this debilitating disease.” worldtruth.tv
No comments:
Post a Comment